Zobrazeno 1 - 10
of 170
pro vyhledávání: '"Michael, Hudecek"'
Autor:
Florian Märkl, Christoph Schultheiß, Murtaza Ali, Shih-Shih Chen, Marina Zintchenko, Lukas Egli, Juliane Mietz, Obinna Chijioke, Lisa Paschold, Sebastijan Spajic, Anne Holtermann, Janina Dörr, Sophia Stock, Andreas Zingg, Heinz Läubli, Ignazio Piseddu, David Anz, Marcus Dühren-von Minden, Tianjiao Zhang, Thomas Nerreter, Michael Hudecek, Susana Minguet, Nicholas Chiorazzi, Sebastian Kobold, Mascha Binder
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-14 (2024)
Abstract The concept of precision cell therapy targeting tumor-specific mutations is appealing but requires surface-exposed neoepitopes, which is a rarity in cancer. B cell receptors (BCR) of mature lymphoid malignancies are exceptional in that they
Externí odkaz:
https://doaj.org/article/f556d70ecba646069501e54817da7995
Autor:
Umair Munawar, Xiang Zhou, Sabrina Prommersberger, Silvia Nerreter, Cornelia Vogt, Maximilian J. Steinhardt, Marietta Truger, Julia Mersi, Eva Teufel, Seungbin Han, Larissa Haertle, Nicole Banholzer, Patrick Eiring, Sophia Danhof, Miguel Angel Navarro-Aguadero, Adrian Fernandez-Martin, Alejandra Ortiz-Ruiz, Santiago Barrio, Miguel Gallardo, Antonio Valeri, Eva Castellano, Peter Raab, Maximilian Rudert, Claudia Haferlach, Markus Sauer, Michael Hudecek, J. Martinez-Lopez, Johannes Waldschmidt, Hermann Einsele, Leo Rasche, K. Martin Kortüm
Publikováno v:
Communications Biology, Vol 6, Iss 1, Pp 1-9 (2023)
Abstract The treatment landscape in multiple myeloma (MM) is shifting from genotoxic drugs to immunotherapies. Monoclonal antibodies, immunoconjugates, T-cell engaging antibodies and CART cells have been incorporated into routine treatment algorithms
Externí odkaz:
https://doaj.org/article/91aba52b6c244a118ef7a4278eff963f
Autor:
Daria Shevtsova, Anam Ahmed, Iris W A Boot, Carmen Sanges, Michael Hudecek, John J L Jacobs, Simon Hort, Hubertus J M Vrijhoef
Publikováno v:
JMIR Human Factors, Vol 11, p e47031 (2024)
BackgroundArtificial intelligence (AI)–powered technologies are being increasingly used in almost all fields, including medicine. However, to successfully implement medical AI applications, ensuring trust and acceptance toward such technologies is
Externí odkaz:
https://doaj.org/article/dbd626d0294048c38dce54fea962e7ca
Autor:
Benno Lickefett, Lulu Chu, Valentin Ortiz-Maldonado, Linda Warmuth, Pere Barba, Matteo Doglio, David Henderson, Michael Hudecek, Andreas Kremer, Janet Markman, Magdalena Nauerth, Helene Negre, Carmen Sanges, Philipp B. Staber, Rebecca Tanzi, Julio Delgado, Dirk H. Busch, Jürgen Kuball, Maik Luu, Ulrich Jäger
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
Lymphodepletion (LD) or conditioning is an essential step in the application of currently used autologous and allogeneic chimeric antigen receptor T-cell (CAR-T) therapies as it maximizes engraftment, efficacy and long-term survival of CAR-T. Its mai
Externí odkaz:
https://doaj.org/article/867d97eccd50488c8737f46f9637a5f0
Autor:
Delphine Ammar, Inga Schapitz, Maik Luu, Michael Hudecek, Miriam Meyer, Timmothy Taps, Bernd Schröder, Zoltán Ivics, Carmen Sanges, Paul Franz, Ulrike Koehl, Helene Negre, Inez Johanna, Jacquelyn Awigena-Cook
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
To accelerate the development of Advanced Therapy Medicinal Products (ATMPs) for patients suffering from life-threatening cancer with limited therapeutic options, regulatory approaches need to be constantly reviewed, evaluated and adjusted, as necess
Externí odkaz:
https://doaj.org/article/5d384e6985d7461ba55323e181207b7d
Autor:
Anna Christina Dragon, Luca Marie Beermann, Melina Umland, Agnes Bonifacius, Chiara Malinconico, Louisa Ruhl, Patrik Kehler, Johanna Gellert, Lisa Weiß, Sarah Mayer-Hain, Katharina Zimmermann, Sebastian Riese, Felicitas Thol, Gernot Beutel, Britta Maecker-Kolhoff, Fumiichiro Yamamoto, Rainer Blasczyk, Axel Schambach, Michael Hust, Michael Hudecek, Britta Eiz-Vesper
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
IntroductionChimeric antigen receptor-engineered T cells (CAR-Ts) are investigated in various clinical trials for the treatment of cancer entities beyond hematologic malignancies. A major hurdle is the identification of a target antigen with high exp
Externí odkaz:
https://doaj.org/article/46ba9e9337d34affb73dc677378f3afa
Autor:
Sarah Staudt, Kai Ziegler-Martin, Alexander Visekruna, John Slingerland, Roni Shouval, Michael Hudecek, Marcel van den Brink, Maik Luu
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
The opportunities genetic engineering has created in the field of adoptive cellular therapy for cancer are accelerating the development of novel treatment strategies using chimeric antigen receptor (CAR) and T cell receptor (TCR) T cells. The great s
Externí odkaz:
https://doaj.org/article/c3512a04084f460ca535deb941c644e6
Publikováno v:
HemaSphere, Vol 7, p e35823f7 (2023)
Externí odkaz:
https://doaj.org/article/3f5e2adb149b4b6f8fc0aa8dc438cb55
Autor:
Anna Bielowski, Teresa Kilian, Sarah Rümpeler Calheiros Vera-Cruz, Zeno Riester, Sabrina Prommersberger, Julia Beckmann, Martin Kortüm, Leo Rasche, Hermann Einsele, Michael Hudecek, Sophia Danhof
Publikováno v:
HemaSphere, Vol 7, p e5328352 (2023)
Externí odkaz:
https://doaj.org/article/d8e4727760a9497291bbf1b9a961fa90
Autor:
Estefanía García-Guerrero, Luis G. Rodríguez-Lobato, Belén Sierro-Martínez, Sophia Danhof, Stephan Bates, Silke Frenz, Larissa Haertle, Ralph Götz, Markus Sauer, Leo Rasche, K. Martin Kortüm, Jose A. Pérez-Simón, Hermann Einsele, Michael Hudecek, Sabrina R. Prommersberger
Publikováno v:
Haematologica, Vol 108, Iss 2 (2022)
B-cell maturation antigen (BCMA) is the lead antigen for chimeric antigen receptor (CAR) T-cell therapy in multiple myeloma (MM). A challenge is inter- and intra-patient heterogeneity in BCMA expression on MM cells and BCMA downmodulation under thera
Externí odkaz:
https://doaj.org/article/c5afb352d346406386ae305b8e18e44f